Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation

Goetz, M.P., Wander, S.A., Bachelot, T. et al. (17 more authors) (2024) Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. American Society of Clinical Oncology. ISSN: 0732-183X. EISSN: 1527-7755.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
  • Goetz, M.P.
  • Wander, S.A.
  • Bachelot, T.
  • Batist, G.
  • Cortes, J.
  • Cristofanilli, M.
  • Curigliano, G.
  • De Nonneville, A.
  • Gal-Yam, E.N.
  • Jhaveri, K.L.
  • Ma, C.X.
  • Parsons, H.A.
  • Rugo, H.S.
  • Sammons, S.L.
  • Stover, D.G.
  • Twelves, C.
  • Bardia, A.
  • Plourde, P.V.
  • Portman, D.J.
  • Damodaran, S.
Dates:
  • Published (online): 29 May 2024
  • Published: June 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Date Deposited: 27 Oct 2025 16:38
Last Modified: 27 Oct 2025 16:38
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: 10.1200/JCO.2024.42.16_suppl.TPS1127
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)